VistaGen Therapeutics, Inc.
VTGNAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Dec 17, 2025 | Jefferies | Andrew Tsai | $0.90(+5%) | $0.86 | StreetInsider |
| Dec 17, 2025 | Stifel Nicolaus | $1.00(+26%) | $0.79 | TheFly | |
| Nov 17, 2025 | Stifel Nicolaus | Paul Mattheis | $12.00(+161%) | $4.59 | StreetInsider |
| Jul 22, 2022 | Jefferies | Andrew Tsai | $0.20(-95%) | $4.38 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Jefferies | downgrade | Buy →Hold | Dec 17, 2025 |
| William Blair | downgrade | Outperform →Market Perform | Dec 17, 2025 |
| Maxim Group | downgrade | Buy →Hold | Dec 17, 2025 |
| Jefferies | upgrade | Hold →Buy | Dec 7, 2023 |
| Maxim Group | maintain | Buy | Sep 5, 2023 |
| Maxim Group | upgrade | Hold →Buy | Aug 7, 2023 |
| Maxim Group | downgrade | Buy →Hold | Jul 26, 2022 |
| William Blair | downgrade | Outperform →Market Perform | Jul 22, 2022 |
| Baird | maintain | Outperform | May 20, 2021 |
| Jefferies | maintain | Buy | Feb 18, 2021 |
| William Blair | upgrade | Market Perform →Outperform | Jan 4, 2021 |
| Aegis Capital | maintain | Buy | Oct 8, 2020 |
| William Blair | maintain | Outperform | Aug 28, 2019 |
| Chardan Capital | downgrade | Buy →Neutral | Jul 22, 2019 |
| Maxim Group | maintain | Buy | Jun 27, 2018 |
| Oppenheimer | maintain | Outperform | May 24, 2018 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.38| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.30 | $-0.36 | $1.5M | $500.0K |
| Jun 15, 2026 | $-0.37 | $-0.42 | $464.0K | $399.9K |
| Feb 12, 2026 | $-0.45 | $-0.51 | $303.0K | $364.4K |
| Nov 13, 2025 | $-0.54 | $-0.51 | $258.0K | $145.8K |
| Aug 7, 2025 | $-0.47 | $-0.47 | $244.0K | $215.7K |
| Jun 17, 2025 | $-0.43 | $-0.52 | -$15.0K | $209.3K |
| Feb 13, 2025 | $-0.46 | $-0.48 | $234.0K | $182.0K |
| Nov 7, 2024 | $-0.42 | $-0.40 | $183.0K | $240.0K |
News
VistaGen Therapeutics, Inc. (NASDAQ: VTGN - Get Free Report) saw a significant decline in short interest in the month of October. As of October 15th, there was short interest totaling 2,472,435 shares, a decline of 34.1% from the September 30th total of 3,750,912 shares. Currently, 5.7% of the company's shares are sold short. Based on an
Collaboration combines Vistagen's neuroscience expertise and datasets with GATC Health's predictive modeling capabilities to provide additional insights for protocol development and resource allocation Collaboration combines Vistagen's neuroscience expertise and datasets with GATC Health's predictive modeling capabilities to provide additional insights for protocol development and resource allocation
Options traders are buying the dip in two stocks this morning, with Meta Platforms (NASDAQ:META) and Vistagen Therapeutics (NASDAQ:VTGN) drawing bullish options activity as both equities trade lower.
Exploratory research results presented at Psych Congress 2026 in New Orleans Full poster presentation can be found on “Publications” section of Company's website SOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented positive exploratory data at Psych Congress 2026 in New Orle…
Vistagen Inc. (NASDAQ:VTGN) surged on Wednesday after preliminary findings from the open-label extension portion of its PALISADE-4 Phase 3 trial evaluating intranasal fasedienol for acute social anxiety disorder.
Fasedienol nasal spray was well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use for up to 12 months
Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder
Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies